# Panobinostat Maintenance After HSCT fo High-risk AML and MDS

> **NCT04326764** · PHASE3 · TERMINATED · sponsor: **Goethe University** · enrollment: 52 (actual)

## Conditions studied

- Acute Myeloid Leukaemia (AML)
- Myelodysplastic Syndromes (MDS)

## Interventions

- **DRUG:** Panobinostat

## Key facts

- **NCT ID:** NCT04326764
- **Lead sponsor:** Goethe University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-24
- **Primary completion:** 2023-02-13
- **Final completion:** 2023-02-13
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** Change of marketing authorisation holder
- **Last updated:** 2023-02-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04326764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04326764, "Panobinostat Maintenance After HSCT fo High-risk AML and MDS". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04326764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*